Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-3.A1 peptide + CpG 7909
- Development stage
- Unknown
- Lead developer
- Cliniques universitaires Saint-Luc
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal, Intravenous
01
Overview
A cancer vaccine combination consisting of MAGE-3.A1 peptide (EVDPIGHLY) derived from human melanoma antigen 3 (MAGE-3) and CpG 7909, an adjuvant. The MAGE-3.A1 peptide is recognized by cytolytic T lymphocytes when presented by HLA-A*0101 or HLA-B*3501. This combination aims to induce tumor-specific immune responses against cancers expressing MAGE-3, particularly melanoma.
- Other names
- MAGE-3.A1/CpG 7909 vaccineMAGE-3.A1 peptide vaccineMAGE3.A1 peptide vaccineMAGE 3.A1 peptide vaccineLudwig Institute MAGE-3 vaccine
02
Targets
HLA-A*01 (Human leukocyte antigen A*01:01)MAGE-A3 TCR (T cell receptor / peptide–MHC complex derived from MAGE-A3/A6)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on MAGE-3.A1 peptide + CpG 7909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-3.A1 peptide + CpG 7909.